We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-6.17%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.29B
AUM Growth
-$232M
Cap. Flow
+$49.5M
Cap. Flow %
3.84%
Top 10 Hldgs %
64.8%
Holding
49
New
12
Increased
11
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$19.3M
2
NVTA
Invitae Corporation
NVTA
+$19.3M
3
TSVT
2seventy bio
TSVT
+$17.4M
4
TWST icon
Twist Bioscience
TWST
+$16.8M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$14.6M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$60.4M
2
RLAY icon
Relay Therapeutics
RLAY
+$31.6M
3
VERV
Verve Therapeutics
VERV
+$23.5M
4
EXAS
Exact Sciences
EXAS
+$16.4M
5
BPMC
Blueprint Medicines
BPMC
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
1
Sarepta Therapeutics
SRPT
$1.63B
$170M 13.2%
1,315,000
+90,000
+7% +$10.4M
BLFS icon
2
BioLife Solutions
BLFS
$1.56B
$138M 10.67%
7,566,292
– –
EQRX
3
DELISTED
EQRx, Inc. Common Stock
EQRX
$97.2M 7.53%
39,527,669
– –
ALNY icon
4
Alnylam Pharmaceuticals
ALNY
$29.1B
$86.7M 6.72%
365,000
-283,000
-44% -$60.4M
ILMN icon
5
Illumina
ILMN
$30.2B
$77.8M 6.03%
395,780
– –
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$64.7M 5.02%
1,477,800
-222,200
-13% -$10.7M
RVMD icon
7
Revolution Medicines
RVMD
$38.8B
$60.1M 4.66%
2,525,000
+2,700
+0.1% +$57.4K
MXCT icon
8
MaxCyte
MXCT
$116M
$51.9M 4.02%
9,505,000
-1,230,786
-11% -$7.55M
RLAY icon
9
Relay Therapeutics
RLAY
$4.04B
$45.3M 3.51%
3,030,648
-1,652,784
-35% -$31.6M
VERV
10
DELISTED
Verve Therapeutics
VERV
$44.3M 3.43%
2,290,571
-887,596
-28% -$23.5M
DNLI icon
11
Denali Therapeutics
DNLI
$3.67B
$36.2M 2.8%
1,300,000
+305,000
+31% +$9.08M
PLRX icon
12
Pliant Therapeutics
PLRX
$64.4M
$32.4M 2.51%
1,675,000
+925,000
+123% +$19.3M
SLGC
13
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$31.6M 2.45%
12,604,275
– –
EXAS
14
DELISTED
Exact Sciences
EXAS
$28M 2.17%
565,000
-402,000
-42% -$16.4M
ABCL icon
15
AbCellera Biologics
ABCL
$1.78B
$23M 1.78%
2,270,000
+620,000
+38% +$7.16M
TWST icon
16
Twist Bioscience
TWST
$5.97B
$22.5M 1.74%
945,000
+580,000
+159% +$16.8M
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$21.5M 1.67%
475,000
+225,000
+90% +$14.6M
FATE icon
18
Fate Therapeutics
FATE
$294M
$20.7M 1.6%
2,050,000
– –
RNAM
19
DELISTED
Avidity Biosciences
RNAM
$18.9M 1.46%
+850,000
New +$12.7M
TSVT
20
DELISTED
2seventy bio
TSVT
$17.3M 1.34%
1,850,000
+1,235,246
+201% +$17.4M
NVTA
21
DELISTED
Invitae Corporation
NVTA
$16.8M 1.3%
9,038,388
+7,912,500
+703% +$19.3M
RXDX
22
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$16.5M 1.28%
+150,000
New +$9.73M
IPSC icon
23
Century Therapeutics
IPSC
$353M
$16.4M 1.27%
3,206,380
– –
ABSI icon
24
Absci
ABSI
$1.34B
$15.5M 1.2%
7,363,260
-355,333
-5% -$972K
BEAM icon
25
Beam Therapeutics
BEAM
$2.66B
$14.5M 1.12%
370,000
– –
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Casdin Capital held 49 positions worth $1.29B, down 15% from $1.52B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Casdin Capital deployed $49.5M of net new capital in Q4 2022, opening 12 new positions and adding to 11 existing holdings. Its largest new stake was Prime Medicine: 734,350 shares worth $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $60.4M trimmed.

  • Casdin Capital's largest Q4 2022 buy was Prime Medicine: 734,350 shares worth $13.6M.
  • Casdin Capital added most to Pliant Therapeutics in Q4 2022, an estimated $19.3M increase.
  • Casdin Capital's biggest Q4 2022 reduction was Alnylam Pharmaceuticals, cutting an estimated $60.4M.
  • Casdin Capital fully exited Celldex Therapeutics in Q4 2022, selling an estimated $4.64M.
  • Casdin Capital's ten largest holdings make up 65% of its $1.29B portfolio in Q4 2022.
  • Casdin Capital opened 12 new positions and closed 3 in Q4 2022.
  • Casdin Capital's portfolio value fell 15% quarter-over-quarter to $1.29B.

Based on Casdin Capital's 13F filing for Q4 2022, filed 14 Feb 2023.